| 名稱(chēng) | ETV6-NTRK3/BaF3 |
| 型號(hào) | CBP73194 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | ETV6-NTRK3/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- 新型冠狀病毒：用于診斷的假病毒標(biāo)準(zhǔn)品和用于藥物研發(fā)的假病毒模型
- 【藥靶模型】ESR1 Y537S模型開(kāi)發(fā)
- 重磅！科學(xué)家成功利用免疫細(xì)胞運(yùn)輸抗癌藥物至腫瘤靶點(diǎn)
- 細(xì)胞株開(kāi)發(fā)的主要過(guò)程要知道
- 潛力十足的T細(xì)胞療法，我們用得起嗎？
- IL9細(xì)胞篩選模型
- 基于納米顆粒的組合免疫療法對(duì)致命性癌癥發(fā)起三重打擊
- BTK細(xì)胞篩選模型
- 能量平衡的重要靶點(diǎn)——CRF1R和CRF2R
- MTHFR基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： [email protected]
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： [email protected]
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73194ETV6-NTRK3/BaF3
- 詳細(xì)內(nèi)容
CBP73194 | |
| I. Introduction | |
Cell Line Name： | ETV6-NTRK3/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10% FBS+1 ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
| ETV6-NTRK3 gene fusion is the translocation of genetic material between the ETV6 gene located on the short arm (designated p) of chromosome 12 at position p13.2 (i.e. 12p13.2) and the NTRK3 gene located on the long arm (designated q) of chromosome 15 at position q25.3 (i.e. 15q25.3) to create the (12;15)(p13;q25) fusion gene, ETV6-NTRK3. This new gene consists of the 5' end of ETV6 fused to the 3' end of NTRK3. ETV6-NTRK3 therefore codes for an chimeric oncoprotein consisting of the helix-loop-helix (HLH) protein dimerization domain of the ETV6 protein fused to the tyrosine kinase (i.e. PTK) domain of the NTRK3 protein. The ETV6 gene codes for the transcription factor protein, ETV6, which suppresses the expression of, and thereby regulates, various genes that in mice are required for normal hematopoiesis as well as the development and maintenance of the vascular network. NTRK3 codes for Tropomyosin receptor kinase C a NT-3 growth factor receptor cell surface protein that when bound to its growth factor ligand, neurotrophin-3, becomes an active tyrosine kinase that phosphorylates tyrosine residues on, and thereby stimulates, signaling proteins that promote the growth, survival, and proliferation of their parent cells. The tyrosine kinase of the ETV6-NTRK3 fusion protein is dysfunctional in that it is continuously active in phophorylating tyrosine residues on, and thereby continuously stimulating, proteins that promote the growth, survival, and proliferation of their parent cells. In consequence, these cells take on malignant characteristics and are on the pathway of becoming cancerous. Indeed, the ETV6-NTRK3 fusion gene appears to be a critical driver of several types of cancers. It was originally identified in congenital fibrosarcoma and subsequently found in secretory breast cancer (also termed juvenile breast cancer), Mammary analogue secretory carcinoma of salivary glands (also termed MASC or MASCSG), congenital fibrosarcoma, congenital mesoblastic nephroma, rare cases of acute myelogenous leukemia, ALK-negative Inflammatory myofibroblastic tumour, and radiation-induced papillary thyroid carcinoma. | |
| III. Representative Data | |
1. WB of ETV6-NTRK3/BaF3 expression | |
| |
2. Anti-proliferation assay | |
| |
Figure 2. Anti-proliferation assay of two reference compounds on the ETV6-NTRK3/BaF3 Stable Cell Line | |
會(huì)員_a.png)